NCT07154914

A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics

Mapping Prostate Cancer Evolution and Therapy Resistance With Single-Cell Technologies

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 396 (estimated)
• Sponsor: Anhui Medical University · Academic / Other
• Sex: Male
• Age: 18 Years – 85 Years
• Healthy volunteers: —

Summary

This study will follow patients with metastatic hormone-sensitive prostate cancer (mHSPC) who receive androgen deprivation therapy (ADT) combined with different treatments. Prostate cancer is a common cancer in men, and many patients in China are diagnosed at an advanced stage. While ADT alone has been the standard treatment, most patients eventually progress to castration-resistant disease. New medicines such as abiraterone, enzalutamide, apalutamide, darolutamide, and chemotherapy like docetaxel have shown survival benefits when added to ADT. This study aims to observe how different ADT-based combinations work in real-world practice and whether genetic differences affect outcomes. About 396 patients will be enrolled and followed until disease progression or death. The results will help identify which treatments are most effective and guide more personalized care for men with advanced prostate cancer.

Conditions

• Metastatic Hormone-Sensitive Prostate Cance

Interventions

Type	Name	Description
DRUG	Abiraterone + ADT	Patients receiving androgen deprivation therapy (ADT) combined with abiraterone. Abiraterone is a CYP17A1 inhibitor used in combination with prednisone and ADT for metastatic hormone-sensitive prostate cancer (mHSPC). This combination is given in real-world practice according to clinical guidelines.

Timeline

• Start date: 2025-09-01
• Primary completion: 2026-09-01
• Completion: 2026-09-01
• First posted: 2025-09-04
• Last updated: 2025-09-04